Example: Heart Attack

Search clinical trials for: Azacitidine

Total 600 results

NCT03873311

Recruiting

Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy

Conditions: Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia
NCT03978364

Recruiting

A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC

Conditions: Myelodysplastic Syndromes,Acute Myeloid Leukemia
NCT02985190

Active, not recruiting

A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders

Conditions: MDS; Systemic Autoimmune Diseases
NCT03666559

Recruiting

Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation

Conditions: Recurrent IDH1/2 Mutated Glioma
NCT03588078

Active, not recruiting

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Conditions: Myelodysplastic Syndrome With Gene Mutation; Acute Myeloid Leukemia With Gene Mutations; Myeloproliferative Neoplasm; Chronic Myelomonocytic Leukemia
NCT02323139

Completed

A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients

Conditions: MDS
NCT01599325

Completed

Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome

Conditions: Myelodysplastic Syndrome (MDS)
NCT01462578

Unknown status

Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)

Conditions: Acute Myelocytic Leukemia; Myelodysplastic Syndrome
NCT03326310

Recruiting

Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia

Conditions: Chronic Myeloid Leukemia; Myelofibroses
NCT02447666

Completed

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Conditions: Myelodysplastic Syndrome; Leukemia, Myelomonocytic, Juvenile
NCT03483948

Terminated

Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT03466294

Active, not recruiting

Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML

Conditions: Acute Myeloid Leukemia
NCT04417517

Recruiting

A Study of ALX148 With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

Conditions: Higher Risk Myelodysplastic Syndromes
NCT02458235

Completed

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

Conditions: Acute Myelogenous Leukemia; Acute Lymphoid Leukemia; Juvenile Myelomonocytic Leukemia; Myelodysplastic Syndrome
NCT02940483

Completed

Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma

Conditions: Brain Tumor Recurrent
NCT04187703

Recruiting

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Conditions: Myelodysplastic Syndromes; MDS/MPN Crossover Syndromes
NCT00901537

Terminated

Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer

Conditions: Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck
NCT01324960

Withdrawn

Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes

Conditions: Myelodysplastic Syndromes
NCT02038816

Terminated

Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)

Conditions: Myelodysplastic Syndromes
NCT01652781

Unknown status

5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome

Conditions: Myelodysplastic Syndrome
NCT01488565

Completed

A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia

Conditions: Myelodysplastic Syndromes (MDS); Acute Myeloid Leukaemia (AML)
NCT02204020

Withdrawn

Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS

Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
NCT04241549

Recruiting

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Conditions: Leukemia, Myeloid, Acute
NCT00795548

Completed

Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation

Conditions: Myelodysplastic Syndrome; Acute Myeloid Leukemia
NCT03397173

Active, not recruiting

TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid

Conditions: Myelodysplastic Syndromes; Myeloproliferative Neoplasm; Acute Myeloid Leukemia